Download PDF
Semin Liver Dis 2015; 35(03): 291-303
DOI: 10.1055/s-0035-1562948
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease

Laurent Castera
1   Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Université Paris-VII, Clichy, France
› Author Affiliations
Further Information

Publication History

Publication Date:
17 September 2015 (online)

   Buy Article Permissions and Reprints
Zoom Image

Abstract

Key issues in patients with nonalcoholic fatty liver disease (NAFLD) are the differentiation of nonalcoholic steatohepatitis (NASH) from simple steatosis and staging of liver fibrosis, as patients with NASH/advanced fibrosis are at greatest risk of developing complications of end-stage liver disease. The controlled attenuation parameter is the most promising noninvasive technique for detecting and quantifying hepatic steatosis, but needs to be implemented with the XL probe and compared with ultrasound that, despite its limitations, remains the most widely used method. Cytokeratin-18 is currently the most extensively validated serum marker of NASH as a stand-alone test or as part of prediction models. However, it is not widely available and thus has not been introduced yet into practice. Transient elastography, as well as FIB-4 and NAFLD fibrosis scores are the best methods to rule out severe fibrosis and cirrhosis. However, the high rate of unreliable results with transient elastography remains a challenge, which is not completely addressed by the use of the XL probe. Given the high prevalence of NAFLD in the general population, these noninvasive methods could be used in clinical practice as first-line tools to screen patients with NAFLD to help determine those who may still require a liver biopsy.

Keywords

nonalcoholic fatty liver disease - noninvasive - steatosis - nonalcoholic steatohepatitis - fibrosis - serum markers - transient elastography